Physician profile
Robert D Loudon
NPI 1487608881
$10,607.66
in general payments reported to CMS, 2019-2025
43 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $783 · 2021: $1,943 · 2022: $1,572 · 2023: $1,317 · 2024: $2,216 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,148 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,681.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,058.20 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $2,025.22 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $914.82 | 2019-2025 | Entyvio |
| Pfizer INC. | $296.46 | 2021-2025 | |
| Genzyme Corporation | $216.13 | 2022-2024 | |
| Celgene Corporation | $202.40 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $162.93 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $151.31 | 2019-2025 | Sucraid |
| Redhill Biopharma INC. | $148.05 | 2020-2022 | |
| Lilly USA, LLC | $143.19 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $126.04 | 2020-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $118.86 | 2020-2021 | |
| Lucid Diagnostics INC. | $112.75 | 2024 | |
| Ardelyx, INC. | $108.69 | 2024-2025 | Ibsrela |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Loudon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.